Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion
10.3760/cma.j.cn121090-20240220-00069
- VernacularTitle:伴t(17;19)(q21-22;p13)/TCF3-HLF急性淋巴细胞白血病7例临床分析
- Author:
Yan PU
1
;
Yin LIU
;
Xiangyue ZHOU
;
Baoquan SONG
;
Jian ZHANG
;
Wanhui YAN
;
Qian WANG
;
Jiannong CEN
;
Hongjie SHEN
;
Qinrong WANG
;
Suning CHEN
;
Jinlan PAN
;
Huiying QIU
Author Information
1. 苏州大学附属第一医院血液内科，江苏省血液研究所，国家血液系统疾病临床医学研究中心，苏州 215006
- From:
Chinese Journal of Hematology
2024;45(9):867-871
- CountryChina
- Language:Chinese
-
Abstract:
A retrospective analysis of the clinical data of seven acute B-lymphoblastic leukemia (B-ALL) patients with TCF3-HLF fusion gene-positive admitted to the First Affiliated Hospital of Soochow University from June 2017 to August 2022 was conducted to summarize their clinical features and prognoses. The seven B-ALL patients comprised four males and three females, with a median age of 18 (11-33) years. Five patients tested positive for CD33 expression, and four patients had a normal karyotype. Two patients had hypercalcemia at the initial diagnosis, and one patient developed hypercalcemia at relapse. Six patients presented with coagulation dysfunction at diagnosis. After induction chemotherapy, five out of seven patients achieved complete remission, of which four subsequently relapsed. Two patients did not achieve remission even after two rounds of induction chemotherapy, with one achieving complete remission after treatment with blinatumomab immunotherapy. Three patients underwent chimeric antigen receptor T cell therapy, whereas three patients subsequently underwent hematopoietic stem cell transplantation. Five patients died, while two patients survived with sustained complete remission. TCF3-HLF-positive B-ALL is rare and has a high relapse rate and poor prognosis.
